Key Takeaways
- TGA issues warnings for GLP-1 RA medicines like Ozempic and Mounjaro.
- 36 cases reported of a ‘rare but severe’ eye condition, NAION.
- Regulator advises caution with use of these medications.
Australia’s Therapeutic Goods Administration (TGA) has issued warnings for several diabetes and weight loss drugs, including Ozempic and Mounjaro, due to a potential link to a rare but severe eye disorder. The warning follows the identification of 36 cases in Australia where patients using GLP-1 receptor agonist (GLP-1 RA) medications experienced a condition known as non-arteritic anterior ischemic optic neuropathy (NAION).
The TGA has updated product information for these drugs, advising healthcare providers and patients to be vigilant about the symptoms of NAION. The regulator stated that while the risk is low, it is important to monitor any changes in vision or eye health closely.
According to the TGA, GLP-1 RA medicines such as Ozempic, Wegovy, and Mounjaro are commonly prescribed for type 2 diabetes and obesity management. These drugs work by mimicking a hormone that regulates blood sugar levels, but they may also affect blood flow in the eye, leading to NAION.
NAION is an ocular condition characterized by sudden vision loss due to reduced blood flow to the optic nerve. It can be difficult to diagnose early and often leads to permanent vision impairment or blindness if not treated promptly. The TGA’s warning emphasizes the importance of recognizing symptoms such as blurred vision, tunnel vision, or a sudden decrease in peripheral vision.
Healthcare professionals are advised to inform their patients about the potential risks associated with these medications and to seek immediate medical attention if any eye-related issues arise. Patients themselves should also be aware of the signs and report any changes in their vision promptly.
The TGA’s decision to issue this warning underscores the ongoing need for vigilance in managing diabetes and obesity, particularly when using GLP-1 RA drugs. The regulator continues to monitor the situation closely and will provide further updates as necessary.
